Frazier Life Sciences Management L.P. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 885,165 shares of the company’s stock after acquiring an additional 271,122 shares during the […]
KPP Advisory Services LLC raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,196 shares of the company’s stock after buying an additional 1,675 shares during the quarter. KPP […]
KPP Advisory Services LLC boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 17.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,196 shares of the company’s stock after purchasing an additional 1,675 shares during the quarter. KPP Advisory Services LLC’s […]
Rhenman & Partners Asset Management AB lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 53.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 100,400 shares of the company’s stock after selling 114,600 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Apellis Pharmaceuticals were […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […]